Engineered insulin-like growth factor-1 for improved smooth muscle regeneration

Kristen M. Lorentz, Lirong Yang, Peter Frey, Jeffrey A. Hubbell

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Insulin-like growth factor-1 (IGF-1) has been shown to induce potent mitogenic responses in various cell types, yet its sustained local delivery is still an underdeveloped domain in the clinic. We report here an engineered IGF-1 that facilitates extended local delivery to a site through its immobilization capacity within fibrin. Through recombinant fusion with a substrate sequence tag derived from α2-plasmin inhibitor (α2PI1-8), the resulting variant, α2PI1-8-IGF-1, was covalently incorporated into fibrin matrices during normal thrombin/factor XIIIa-mediated polymerization. Bioactivity of the variant was confirmed to be equivalent to wild type (WT) IGF-1 via IGF-1 receptor phosphorylation and cell proliferation studies in urinary tract-derived cells in 2-D. Assessment of functional retention within 3-D fibrin matrices demonstrated that incorporation of α2PI1-8-IGF-1 induced a 1.3- and 1.5-fold more robust proliferative response in smooth muscle cells (SMCs) than WT IGF-1 and negative control matrices, respectively, when release was not contained. Sustained α2PI1-8-IGF-1 availability at bladder lesion sites in vivo evoked a considerable increase in SMC proliferation and a favorable host tissue response after 28 days in rats. We conclude that the sustained local IGF-1 availability from fibrin provided by our variant protein enhances smooth muscle regeneration better than the WT form of the protein.

Original languageEnglish
Pages (from-to)494-503
Number of pages10
JournalBiomaterials
Volume33
Issue number2
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Insulin
Somatomedins
Smooth Muscle
Muscle
Regeneration
Fibrin
Cell proliferation
Smooth Muscle Myocytes
Cell Proliferation
Factor XIIIa
Somatomedin Receptors
Availability
Antifibrinolytic Agents
Proteins
Intercellular Signaling Peptides and Proteins
Phosphorylation
Urinary Tract
Thrombin
Polymerization
Immobilization

Keywords

  • Bladder tissue engineering
  • Fibrin
  • Growth factors
  • In vivo test
  • Recombinant protein
  • Smooth muscle cell

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. / Lorentz, Kristen M.; Yang, Lirong; Frey, Peter; Hubbell, Jeffrey A.

In: Biomaterials, Vol. 33, No. 2, 01.01.2012, p. 494-503.

Research output: Contribution to journalArticle

Lorentz, Kristen M. ; Yang, Lirong ; Frey, Peter ; Hubbell, Jeffrey A. / Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. In: Biomaterials. 2012 ; Vol. 33, No. 2. pp. 494-503.
@article{e4e6473a841641b7b1cfa3168c230aa2,
title = "Engineered insulin-like growth factor-1 for improved smooth muscle regeneration",
abstract = "Insulin-like growth factor-1 (IGF-1) has been shown to induce potent mitogenic responses in various cell types, yet its sustained local delivery is still an underdeveloped domain in the clinic. We report here an engineered IGF-1 that facilitates extended local delivery to a site through its immobilization capacity within fibrin. Through recombinant fusion with a substrate sequence tag derived from α2-plasmin inhibitor (α2PI1-8), the resulting variant, α2PI1-8-IGF-1, was covalently incorporated into fibrin matrices during normal thrombin/factor XIIIa-mediated polymerization. Bioactivity of the variant was confirmed to be equivalent to wild type (WT) IGF-1 via IGF-1 receptor phosphorylation and cell proliferation studies in urinary tract-derived cells in 2-D. Assessment of functional retention within 3-D fibrin matrices demonstrated that incorporation of α2PI1-8-IGF-1 induced a 1.3- and 1.5-fold more robust proliferative response in smooth muscle cells (SMCs) than WT IGF-1 and negative control matrices, respectively, when release was not contained. Sustained α2PI1-8-IGF-1 availability at bladder lesion sites in vivo evoked a considerable increase in SMC proliferation and a favorable host tissue response after 28 days in rats. We conclude that the sustained local IGF-1 availability from fibrin provided by our variant protein enhances smooth muscle regeneration better than the WT form of the protein.",
keywords = "Bladder tissue engineering, Fibrin, Growth factors, In vivo test, Recombinant protein, Smooth muscle cell",
author = "Lorentz, {Kristen M.} and Lirong Yang and Peter Frey and Hubbell, {Jeffrey A.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.biomaterials.2011.09.088",
language = "English",
volume = "33",
pages = "494--503",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Engineered insulin-like growth factor-1 for improved smooth muscle regeneration

AU - Lorentz, Kristen M.

AU - Yang, Lirong

AU - Frey, Peter

AU - Hubbell, Jeffrey A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Insulin-like growth factor-1 (IGF-1) has been shown to induce potent mitogenic responses in various cell types, yet its sustained local delivery is still an underdeveloped domain in the clinic. We report here an engineered IGF-1 that facilitates extended local delivery to a site through its immobilization capacity within fibrin. Through recombinant fusion with a substrate sequence tag derived from α2-plasmin inhibitor (α2PI1-8), the resulting variant, α2PI1-8-IGF-1, was covalently incorporated into fibrin matrices during normal thrombin/factor XIIIa-mediated polymerization. Bioactivity of the variant was confirmed to be equivalent to wild type (WT) IGF-1 via IGF-1 receptor phosphorylation and cell proliferation studies in urinary tract-derived cells in 2-D. Assessment of functional retention within 3-D fibrin matrices demonstrated that incorporation of α2PI1-8-IGF-1 induced a 1.3- and 1.5-fold more robust proliferative response in smooth muscle cells (SMCs) than WT IGF-1 and negative control matrices, respectively, when release was not contained. Sustained α2PI1-8-IGF-1 availability at bladder lesion sites in vivo evoked a considerable increase in SMC proliferation and a favorable host tissue response after 28 days in rats. We conclude that the sustained local IGF-1 availability from fibrin provided by our variant protein enhances smooth muscle regeneration better than the WT form of the protein.

AB - Insulin-like growth factor-1 (IGF-1) has been shown to induce potent mitogenic responses in various cell types, yet its sustained local delivery is still an underdeveloped domain in the clinic. We report here an engineered IGF-1 that facilitates extended local delivery to a site through its immobilization capacity within fibrin. Through recombinant fusion with a substrate sequence tag derived from α2-plasmin inhibitor (α2PI1-8), the resulting variant, α2PI1-8-IGF-1, was covalently incorporated into fibrin matrices during normal thrombin/factor XIIIa-mediated polymerization. Bioactivity of the variant was confirmed to be equivalent to wild type (WT) IGF-1 via IGF-1 receptor phosphorylation and cell proliferation studies in urinary tract-derived cells in 2-D. Assessment of functional retention within 3-D fibrin matrices demonstrated that incorporation of α2PI1-8-IGF-1 induced a 1.3- and 1.5-fold more robust proliferative response in smooth muscle cells (SMCs) than WT IGF-1 and negative control matrices, respectively, when release was not contained. Sustained α2PI1-8-IGF-1 availability at bladder lesion sites in vivo evoked a considerable increase in SMC proliferation and a favorable host tissue response after 28 days in rats. We conclude that the sustained local IGF-1 availability from fibrin provided by our variant protein enhances smooth muscle regeneration better than the WT form of the protein.

KW - Bladder tissue engineering

KW - Fibrin

KW - Growth factors

KW - In vivo test

KW - Recombinant protein

KW - Smooth muscle cell

UR - http://www.scopus.com/inward/record.url?scp=80055104248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055104248&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2011.09.088

DO - 10.1016/j.biomaterials.2011.09.088

M3 - Article

C2 - 22014943

AN - SCOPUS:80055104248

VL - 33

SP - 494

EP - 503

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 2

ER -